CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Barcelona, Spain and 125 other locations
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
Barcelona, Spain and 46 other locations
positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...
Phase 2
Barcelona, Spain and 70 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Barcelona, Catalunya, Spain and 92 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
Barcelona, Spain and 176 other locations
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...
Phase 3
Barcelona, Spain and 76 other locations
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer...
Phase 3
Barcelona, Cataluña, Spain and 133 other locations
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian...
Phase 2
Barcelona, Spain and 20 other locations
with either niraparib or lartesertib in participants with epithelial ovarian cancer. The participants will previously have progress...
Phase 2
Barcelona, Spain and 57 other locations
placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1s...
Phase 3
Barcelona, Spain and 110 other locations
Clinical trials
Research sites
Resources
Legal